Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer

JAMA ◽  
1995 ◽  
Vol 274 (8) ◽  
pp. 626 ◽  
Author(s):  
Peter C. Albertsen
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Term Survival ◽  
Long Term Survival

Long-term survival following radical prostatectomy in Japanese men with clinically localized prostate cancer: A single institutional study

2004 ◽  
Vol 11 (10) ◽  
pp. 862-869 ◽  
Author(s):  
TAKAHIKO HACHIYA ◽  
YASUHIRO OKADA ◽  
NOZOMU KAWATA ◽  
DAISAKU HIRANO ◽  
TOSHIO YOSHIDA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Localized Prostate Cancer ◽  
Term Survival ◽  
Japanese Men ◽  
Long Term Survival

The influence of race and treatment choice in 16,508 men treated either conservatively, with radiotherapy, or surgically for clinically localized prostate cancer.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 210-210
Author(s):  
P. Sooriakumaran ◽  
T. Field ◽  
M. John ◽  
R. Leung ◽  
A. Tewari
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Watchful Waiting ◽  
The United States ◽  
Research Network ◽  
Localized Prostate Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Treatment Choices

210 Background: There are known variations in cancer survival based on race and treatment choices. We report the long-term survival probability, based on race, in 16,508 men with localized prostate cancer treated either conservatively or by radiotherapy or radical prostatectomy. Methods: We extracted survival data from tumor registries of six Cancer Research Network sites in the United States. Patients were stratified into four racial groups: Caucasians, African Americans, Hispanics, and Asians. The Cox proportional-hazards regression model was used to compare long-term survival in the three treatment groups. Kaplan-Meier survival curves and competing risk analysis was also performed. Results: Survival was improved for patients who underwent radical prostatectomy compared to radiotherapy or watchful waiting. This was true for all patients combined (Table) as well as for all races individually. Radiotherapy had at least equivalent survival outcomes as watchful waiting in all groups. The differences between treatments were greater for overall survival than for prostate cancer specific survival in all groups, though the extent of the differences varied by race. Conclusions: Radical prostatectomy increases survival in men with localized prostate cancer compared to both radiotherapy and watchful waiting, especially for Caucasian men. Radiotherapy was at least equivalent to watchful waiting for all races. Racial disparities in outcome may influence treatment choices for men with clinically localized prostate cancer. [Table: see text] [Table: see text]

scholarly journals 385: Impact of Socioeconomic Factors on long-term Survival in Patients with Clinically Localized Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 128-128
Author(s):  
Peter Chang ◽  
Ashutosh K. Tewari ◽  
Heather T. Gold ◽  
Wolfgang Hominger ◽  
Alexandre E. Pelzer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Socioeconomic Factors ◽  
Localized Prostate Cancer ◽  
Term Survival ◽  
Long Term Survival

Biochemical failure after treatment for localized prostate cancer: Does original therapeutic modality affect long-term survival?

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 65-65
Author(s):  
Chad A. Reichard ◽  
Evan Kovac ◽  
Jay P. Ciezki ◽  
Rahul D. Tendulkar ◽  
Eric A. Klein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Biochemical Failure ◽  
Localized Prostate Cancer ◽  
Definitive Treatment ◽  
Rank Test ◽  
Cancer Specific Survival ◽  
Term Survival ◽  
Long Term Survival

65 Background: Mortality among men with biochemical failure (BF) after treatment is variable. We examined the long-term survival of men with BF to determine if differences exist, depending on original treatment modality. Methods: Between 1995 and 2008, 6,084 patients underwent treatment for clinically localized prostate cancer at our institution (4,276 underwent radical prostatectomy (RP); 1,808 underwent EBRT). Clinical information and follow up data was obtained from prospectively maintained databases. Survival was assessed using log rank test. Results: 526 (12%) patients had BF defined by PSA > 0.4 after RP. 326 (18%) patients had BF after EBRT, defined as PSA nadir +2. 197 (60%) of EBRT patients received ADT as neoadjuvant/concurrent/adjuvant therapy. Median overall survival was 154 months (95%CI 148-157) versus 129 months (95%CI 123-135) for RP and EBRT respectively (p<.0001). Median prostate cancer specific survival was 125 months (95%CI 93-148) versus 107 months (95%CI 92-123) for RP and EBRT respectively (p=0.17). There was no difference in prostate cancer specific survival between treatments among patients in D’Amico intermediate and high risk groups. Conclusions: In patients with biochemical recurrence after definitive treatment, patients treated with RP have improved overall survival compared to patients treated with EBRT. However, there is no difference among treatment groups in prostate cancer specific survival.

Sign in / Sign up

Export Citation Format

Share Document